Efficacy, safety, pharmacokinetics and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: A phase II study

PURPOSE: We performed a single-arm phase II study of cediranib, a pan-VEGFR tyrosine kinase inhibitor, in patients with advanced hepatocellular carcinoma (HCC). PATIENTS AND METHODS: Patients with histologically confirmed measurable advanced HCC and adequate hematologic, hepatic, and renal functions...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Zhu, Andrew X., Ancukiewicz, Marek, Supko, Jeffrey G., Sahani, Dushyant V., Blaszkowsky, Lawrence S., Meyerhardt, Jeffrey A., Abrams, Thomas A., McCleary, Nadine Jackson, Bhargava, Pankaj, Muzikansky, Alona, Sheehan, Susan, Regan, Eileen, Vasudev, Eamala, Knowles, Michelle, Fuchs, Charles S., Ryan, David P., Jain, Rakesh K., Duda, Dan G.
Formato: Artigo
Idioma:Inglês
Publicado em: 2013
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3609423/
https://ncbi.nlm.nih.gov/pubmed/23362324
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-12-3041
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados